Ever heard of the cryosphere? Well, neither had we. Apparently its all the frozen water in the world: glaciers, polar caps that sort of thing. Enjoy it while you can, because it may not be around for much longer, reports the Guardian
With stories like the following it is easy to fall into laddish prurience or puritanical dismay. But the whole point of this blog is that we confront data with our feelings suspended and it is in that spirit we offer the following story from the eminently respectable El País
“When the facts change I change my mind” so said the great Economist JM Keynes But actually, this is the distinguishing thought process of Science, as this piece A triumph of scientific self correction” from Nature Briefing shows
In his new book The Ends of Race, humanities scholar Geoffrey Galt Harpham chronicles how people attempted touse science to justify racism in the nineteenth century — and the scientific pushback. “Ultimately, the discrediting of the concept of biological race emerged as a triumph of scientific self-correction,” writes journalist David Silverberg in his review.
If you really want to control a disease, strike at the cause not the symptoms we say So this new work on the origins of the cancer promoting protein KRAS and the enzymes that facilitate it seems to offer another avenue of hope as this excellent report from Technology Networks makes clear
Our showcase today comes from Nature Briefing, that indispensable chronicle of all that is new in discovery and innovation. They call it Atlas reveals Mitochondria in detail, and they bring out the implications for parasite diseases and evolution, but today we just want to riff a little further on the implications in the broader style of this blog. First, here’s their usual summary:
Scientists have mapped in unprecedented detail the proteins that make up the mitochondria in six organisms spanning the tree of life — five single-celled parasites and one plant. In a suite of nine papers, researchers reveal dozens of proteins that are shared among parasites, such as those that cause malaria and sleeping sickness, but not found in humans. The findings could help scientists devise new treatments for these illnesses. The work might also support the hypothesis that mitochondria emerged late in eukaryotic evolution, stoking the long-running debate over the organelles’ origins.
We say: Let’s start with parasite diseases, for they still create a great deal of havoc in the world : Shared parasite‑specific proteins are obvious drug targets. But the deeper implication is strategic: If several parasites rely on the same ancient mitochondrial assemblies, then one drug could hit multiple diseases — malaria, sleeping sickness, leishmaniasis, giardiasis, babesiosis, you name it, by “cutting the power” i.e., taking out the mitochondria of the parasite, in the same way. More generally, any understanding of mitochondrial design and structure offers exciting new possibilities in areas such as cancer therapy-which despite all that has been done in the last 25 years or so, still has as many patients needing help as ever. Better still, the research seems to offer a chance to develop new toolkits for synthetic biology If parasites can run mitochondria with radically different protein sets, then synthetic biologists may eventually be able to engineer and design mitochondria for specific metabolic tasks and perhaps even create hybrid organelles for industrial bioprocessing.
All in all a good day, for that old LSS doctrine: Research in one place nearly always has implications in many others.
One of the things about reading Nature Briefing: they always seem put you au fait with the cutting-edge medical techniques, and the science that drives them, a little way ahead of the mainstream. Which is why we are showcasing their story First for Gene Targeting RNA therapy, not just because it’s interesting in itself, but because it is a beautiful illustration of the progress in RNA based medicine, even since we started this humble little blog six years ago. First, here’s their snippet
An RNA therapy for rare forms of amyotrophic lateral sclerosis (ALS) has shown promising results in the first person to receive it. He experienced improved symptoms and continued to work as a physician a year after starting treatment. Antisense oligonucleotide therapy uses short strands of genetic material to target RNA produced by a faulty gene calledCHCHD10. Roughly 5–10% of people with ALS have a known genetic mutation, and antisense oligonucleotide therapies could someday benefit them and others with neurodegenerative diseases caused by rare mutations.
Now, we admit CHCHD10 is a rare mutation, apparently occurring in less than one per cent of ALS cases. There are many other genes involved among the different types of ALS, and, who knows, maybe some epigenetic and environmental factors as well. But to raise that is to be like a man who has won the lottery complaining that the prize didn’t come gift wrapped in Harvey Nicholls wrapping paper. Because, gentle readers-this is a start and a magnificent one. Better still, it’s part of a much bigger story of RNA based medicine advancing on many fronts. Readers will recall how the sudden arrival of RNA vaccines suddenly lifted the world from its COVID-19 based Slough of Despond in 2021. But astute readers will recall that even before COVID, RNA‑based drugs were quietly succeeding: briefly, we will cite Patisiran , ansiRNA therapy for hereditary amyloidosis;Nusinersen — antisense therapy for spinal muscular atrophy; and Givosiran, and inclisiran — RNA drugs for metabolic and cardiovascular conditions; and then let you go off to do your own reading. Yet this in turn is but part of an even bigger picture, a new frontier if you like, of therapies which we hope might deliver RNA constructs to reduce toxic proteins in motor neurons, use antisense or siRNA to knock down mutant SOD1, C9orf72, or other ALS‑linked genes, and even exploit improved delivery systems (lipid nanoparticles, viral vectors) that can finally reach neural tissue. But time will answer many of these questions
And our takeaway? It’s our usual . Using science, and its simple but effective tools of evidence and reason will always make you feel better. So if you start tinkering with basic research and its funding, you do so at your peril.
One of the most fascinating questions in biology is how multicellular life — all plants, fungi and animals — first arose. Single‑celled organisms had been around for thousands of millions of years, at least from about 3.5 billion years ago, just ~1 billion years after the Earth formed at 4.5 billion years. Bacteria and archaea were already present over 4 billion years ago, quietly running the planet’s chemistry long before anything with limbs or leaves appeared. There are hints of multicellular organisms at around 1.4 billion years – red algae are a possible candidate- but that’s still quite late considering the time available. The brutal truth is that wasn’t until about 600 million years ago that truly multicellular organisms begin to show up in the rocks. How, why and when the Great Organising took place is a mystery still buried deep in time.
One possible clue lies in the kingdom of the archaea — those bacteria‑like beings that are not actually bacteria. A particular branch, the Asgard archaea, may hold the key to how complex cells — and eventually multicellular life — emerged. Today’s Nature Briefing has a short, elegant piece called Meet the Parents on the latest findings, and it offers some intriguing hints about how a bunch of free swimming cells learned to co-operate and thereby sparked the great leap to complexity. Is there a lesson for today in there somewhere perhaps?
Microorganisms from which all complex life might be descended — the Asgard archaea — were discovered in 2015 from DNA in sediments plucked from the bottom of the North Atlantic. Since then, researchers have been painstakingly culturing these exotic organisms and finding lots of surprises along the way.Nature | 11 min read
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a natural defence system found in bacteria, which scientists have turned into a programmable way to edit genes with extraordinary precision. In practice, it comprises two parts: a guide RNA that acts like a GPS to find the exact spot in DNA, and a Cas9 enzyme that acts like molecular scissors to cut the DNA. Once the DNA is cut, scientists can delete, fix, or replace genetic sequences inside a living cell. Our first Cover seems to have been over six years ago (LSS 23 11 20), since when we have noted a startling range practical applications from areas as diverse as horse breeding, and sickle cell medicine, to its relationship with blue sky techniques such as Base Pair editing, CART and programmable therapeutics (LSS passim).
How gratifying then to see CRISPR-based tools now partnered with epigenetics, that other old favourite of these humble pages! Once again the lead is taken by the indispensable Nature Briefing, now our go-to for all new things Scientific Their summary CRISPR’s next act: editing the epigenome tells you most of what you need to know. But some readers may well wish to click on the handy link too
A handful of start-up firms are testing therapies that target specific epigenetic markers — essentially chemical groups that sit on DNA and the proteins that it is wound around — to treat everything from high cholesterol to a rare muscular disorder. Changing these chemical markers can switch genes on or off. Some existing medications influence epigenetic markers, but these drugs act broadly and lack specificity. A new cadre of scientists has found ways to precisely alter the epigenetic signals that influence specific genes.
There is much here to gladden the hearts of all who believe in Reason and Learning. The technique seemingly so radical a few short years ago is not only becoming routine, it is embedding itself into the wider corpus of medical and scientific practice. Practicable applications are multiplying and the opportunities to reduce human and animal suffering are thereby multiplying. If anyone asks us “why do you take such an interest in the progress of the Arts, Sciences and Letters?” one answer we give is: because of things like this.
If you want to know more about epigenetics, or molecular biology in general, then we cannot do better than recommend the works of the great Professor Carey:
Carey, Nessa. The Epigenetics Revolution: How Modern Biology Is Rewriting Our Understanding of Genetics, Disease, and Inheritance.London: Icon Books, 2011. New York: Columbia University Press, 2012. ISBN: 9781848312920 (Icon Books); 9780231530712 (Columbia UP).
Carey, Nessa. Hacking the Code of Life: How Gene Editing Will Rewrite Our Futures.London: Icon Books, 2019. New York: Columbia University Press, 2019. ISBN: 9781785784972 (Icon Books); 9780231549769 (Columbia UP).
The idea of whole and unexpected possibilities in antibiotic research excites our highest hopes-and those of readers who have accompanied us on this journey for years. None more so than this report from Nature BriefingGene Megacluster boosts antibiotic arsenal. We’ve set up their usual summary, plus links: and then we’ll try to answer a few of your questions as best we are able
A newly discovered gene ‘megacluster’ in Streptomyces bacteria enables them to produce a variety of potent antibiotic compounds. These compounds act as a multi-pronged offensive weapon against other species, with each targeting different stages of the bacterial metabolic process. It’s more difficult for bacteria to develop resistance to attacks that hit several targets, so the discovery could lead to the development of new antibiotics, experts say. The research has “discovered something new in a system so extensively studied — hidden in plain sight,” says medicinal chemist Mark Blaskovich
So, what is this gene megacluster? An unusual stretch of DNA in Streptomyces that encodes four distinct families of natural-product antibiotics, including: one compound entirely new to science, another never previously recognised as an antibiotic, and two known families deployed in a new coordinated fashion. Not a bad haul for one discovery, we think.
What does it do in Streptomyces? All four molecules target biotin (vitamin B7)—a universal cofactor required for growth, cell division, and metabolic enzyme function in most bacteria. They attack different points in the biotin pathway: production, uptake, use, and availability, aided by flanking streptavidin genes that bind up free biotin.
Why is this discovery genuinely new? Well , all sorts of reasons: here are a few of the best
–Co-location is unheard of: Antibiotic biosynthetic pathways are usually scattered across the genome. Here, four unrelated antibiotic families sit side-by-side, implying intentional evolutionary selection.
–Coordinated multi-antibiotic strategy: Natural antibiotics typically act alone. This cluster encodes a team of molecules that hit the same vulnerability from different angles—something not previously documented.
–Hidden in plain sight :Streptomyces genomes have been mined for decades, yet this megacluster was overlooked because genome-mining tools historically focused on single-product clusters. We love this bit, as regular readers will have already discerned
–It appears to be widespread. The megacluster is present across multiple Streptomyces species, suggesting an ancient, conserved strategy rather than a rare curiosity.
Could similar clusters exist in other organisms? Likely, yes. The discovery provides a road map for genome mining that looks for coordinated multi-pathway clusters, not just single biosynthetic islands Early research might do better to focus on procaryotes rather than eucaryotes-but who knows?
How could it help us to develop new antibiotics? This is the Big One for us , isn’t it? Lots of ways potentially, but as of late June 2026 three practical routes suggest themselves:
1. Direct development of the four biotin-targeting molecules. Because they attack different steps in the same essential pathway, they could be: used individually, combined as a cocktail, or engineered into hybrid molecules. Multi-target antibiotics are inherently harder for pathogens to resist. So that will teach them we’re serious this time.
2. Synthetic biology reconstruction. The megacluster’s architecture can be transplanted into: Streptomyces strains, E. coli or yeast expression systems, or modular cell-free platforms, permitting all sorts of scaling and production advantages
3. Drug discovery by analogy The discovery provides a template: look for clusters that coordinate attacks on other essential pathways (e.g., folate, isoprenoid synthesis, lipid II). Genome mining guided by this logic could uncover dozens of new multi-pronged antibiotic families.
4. Biotin-pathway inhibitors as a new class Biotin metabolism is conserved across many pathogens, including Gram-negatives—historically hard to target. These molecules could seed a new class of antibiotics that bypass existing resistance mechanisms
At this blog we tend to rate discoveries by the possibilities they open rather than the questions they answer. By that metric, this one is big indeed-and we think you’ll al agree with that.
In these happy, carefree days of 2026, we almost take the success of advanced techniques like CRISPR–Cas9 and CAR‑T for granted. Yet not so long ago they were obscure experimental curiosities, known only inside specialist laboratories. So we asked ourselves: is there something equally obscure in 2026 that will be the stock‑in‑trade of doctors in 2046? We think there might be: programmable cell therapeutics.[1]
The jumping‑off point is the logic behind CAR‑T. Readers will recall how T‑cells are removed from a patient, engineered to recognise the chemical signatures of their cancer, and then reinfused to hunt down malignant cells. Researchers are now extending this idea to a wider cast of immune cells, stem cells, and progenitors, so they can tackle diseases far beyond oncology.
What makes the next generation different is the importation of ideas from electrical engineering. Instead of a single engineered receptor, cells can be fitted with ON/OFF switches, logic gates, multi‑step decision pathways, and feedback loops. In other words, cells that don’t just attack — they compute. They sense the molecular environment, decide what’s happening, and act accordingly.
And thanks to delivery tools such as viral vectors and mRNA‑carrying nanoparticles, these circuits can increasingly be installed in vivo. Rather than the expensive choreography of removing cells, re‑engineering them, and putting them back, the ambition is to program the cell to reprogram itself. Why rebuild the army in the barracks when you can train the soldiers already in the field?
Gentle readers, we are always looking for ways to put you ahead of the curve — not what is happening now, but what will be happening in five, ten, or twenty years’ time. By 2046 we could plausibly see:
cancer therapies that activate only in tumour microenvironments
gene therapies that self‑limit to avoid toxicity
immune cells that make multi‑step decisions
RNA‑based switches that restore gene expression dynamically
All this, of course, depends on continued investment in scientific research and a strong ecosystem of independent universities and research institutes. Hopeful, isn’t it.
Few of us have not met someone who is suffering from Multiple Sclerosis, that terrible wasting disease wherein the immune system seems to turn on its own body, especially in the fatty sheaths around the neurons. Leading to a progressive deterioration in mobility before confining victims finally to a wheelchair-or even worse. The experience for families and victims was extra-bad because for many years the cause seemed unknown, making hope of any cure quite unlikely. Michael Marshall of the New Scientist has been covering this story most assiduously. And so we are pleased to showcase it, because it celebrates achievements in two our our favourite fields-big data and molecular biology-and the benefits which accrue when scientists from both work together.
We urge you to read Michael’s article either by buying the hard copy mag (there’s tons else to read inside it) or paywalling past the link below [1] Suffice it to say:#1The molecular evidence that the Epstein Barr virus (which can cause glandular fever) is involved. #2 That this has a strong effect on both B cells and T cells in the immune system, which ,when they go rogue, are essentially responsible for the terrible lesions of MS #3 That not all hosts of Epstein Barr virus go on to develop MS, because the chances of that depends on certain genetic propensities and variants and, best of all #4 the above and more, which we report so glibly, has been elucidated by the use of huge data studies : 10 million people in one, 617, 186 in another, even 471 000 B cells in another-how’s that for numbers, folks?-which were only possible because: #5 places like the UK and USA have worked to build big collaborative things the the UK Biobank and All of us. Well some of the people in those countries have anyway.
All of which leads us to few reflections, some of which will not be uncongenial to regular readers. Firstly, it seems a pretty good idea to spend money on science, especially basic research, instead of cutting it. Secondly scientists these days work best in large teams whose members come from all sorts of backgrounds and this is especially true when you throw multidisciplinarygroups of them together. And that this also seems to be true of football teams: how far would Arsenal FC. for example, have enjoyed their current success if they had insisted on retaining a staff entirely composed of plucky British lads? [2] The implications in turn for visa systems, cultural openness and plain common sense are clear in turn.
You might be forgiven for thinking we’re against bacteria at this blog. Got a beef with them, want more antibiotics to kill them, especially that pesky little Escherichia coli that is always clogging up the pristine pages of our little website. Nothing could be further from the truth: we are simply against bacteria that kill people, that’s all, and we admire the little creatures for all the useful things they do
Nothing more useful it seems than generating hydrogen in clean green ways that massively reduce greenhouse gas emissions. Of course we need hydrogen for all sorts of things-food, drugs, plastics-but the way it is currently made is depressingly energy intensive Which is what this remarkable team of researchers at Edinburgh University have done, re purposing E coli to make hydrogen in amazingly clean ways Get this extract from the admirable Nature Briefing:
. The new process involves growing a strain of Escherichia coli that naturally produces hydrogen when deprived of oxygen. The researchers added a palladium catalyst and substrate for the hydrogen to bind to, and when they removed oxygen, hydrogen was bound to 94% of the substrate.
And they didn’t stop there:
The team then turned waste bread into a food source that could be given to the bacteria instead of glucose, to show that this type of food waste can be repurposed. The system resulted in a three-fold decrease in greenhouse-gas equivalent emissions compared with using fossil fuels, according to the team’s modelling.
There’s a lot to be said here. First our admiration for the amazing work and intelligence of the scientists[2] whose original paper we seem for once to be able to reproduce in full. The marvellous ways old things like bread and E coli are recycled to useful purposes. And a further point which the team at the admirable Nature Briefing know well. Progress, hope even, comes from the application of the scientific method. The use of evidence and reason to judge it in that order. Nothing else, however much you might want it to be so.
Leber congenital amaurosis, called LCA for short, is the most common form inherited sight loss in children[1] It’s caused by defects in a cluster of genes including RPE65 and until recently was quite untreatable. Now, as Ian Sample reports for the Guardian,[2] a team of researchers have effected a major new treatment called Luxturna: a gene‑replacement therapy delivered by injecting a working copy of the RPE65 gene directly under the retina. By giving retinal cells the functional gene they’re missing, it restores the visual cycle and can improve light sensitivity, visual function, and navigation ability in people with RPE65-related Leber congenital amaurosis. Interestingly the team comprises a husband and wife called Jean Bennett and Albert Maguire who share the prestigious Breakthough Prize [3] with their colleague Katherine High.
Regular readers will share our admiration for the work of this remarkable trio. They may note moreover that the researchers have something else to teach us, something that strongly concurs with opinions often expressed in this blog:
Bennett said it was a “tremendously exciting time” for scientific and medical research, but warned that the US administration’s attacks on science could “cause damage for generations to come”, leading her to fear a brain drain that the country would struggle to recover from.
“Agendas have become politicised, government agencies that support basic and applied research have been undermined, knowledgeable advisers and experts have been dismissed or have fled and revised guidelines contradict decades of rigorous research,”
Says it all really. But don’t just sit around reading it here:tell your friends and neighbours. For us there still remains outstanding question. Is Albert Maguire by any chance a relation of Ken Maguire, one of the best pub landlords of the 1990s, being sometime manager of the superb Latymers in Hammersmith Road London W14?